Department of Respiratory Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Intern Med J. 2011 Dec;41(12):815-24. doi: 10.1111/j.1445-5994.2009.02142.x. Epub 2009 Dec 4.
Performance of linear probe endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for staging non-small-cell lung cancer has been extensively studied. Alternate indications for its use are less well characterised, and performance in other clinical settings may differ.
We examined a prospectively collected cohort comprising the first 215 patients undergoing EBUS-TBNA at our institution. Patients were analysed according to the clinical and radiological indication for referral. We also examined the effect of the procedural learning curve on diagnostic sensitivity.
A total of 215 patients underwent 216 EBUS-TBNA procedures. EBUS-TBNA returned adequate tissue for cytopathological analysis in 202 of 216 procedures (94%). Overall sensitivity for detection of malignancy was 0.92 (95% confidence interval 0.86-0.96); however, this varied according to the primary indication for EBUS-TBNA. Diagnostic sensitivity was high among all sub-groups, but the negative predictive value varied depending on the clinical indication for the procedure. We estimate 104 invasive surgical procedures and 32 inpatient admissions were avoided by use of EBUS-TBNA. Significant improvement in diagnostic performance was seen after 20 procedures were completed, and diagnostic accuracy did not peak until after 50 procedures.
EBUS-TBNA is able to confirm accurately histologically a large number of disease processes, both malignant and benign, in all clinical indications studied. The procedure is safe even when carried out by proceduralists with minimal prior experience. Diagnostic performance continues to improve beyond 50 cases carried out.
线性探头支气管内超声引导经支气管针吸活检(EBUS-TBNA)在非小细胞肺癌分期中的应用性能已得到广泛研究。其替代适应证的特征描述较少,在其他临床环境中的表现可能有所不同。
我们检查了一个前瞻性收集的队列,包括在我们机构进行的前 215 例接受 EBUS-TBNA 的患者。根据转诊的临床和影像学指征对患者进行分析。我们还检查了程序学习曲线对诊断敏感性的影响。
共 215 例患者进行了 216 次 EBUS-TBNA 操作。216 次操作中有 202 次(94%)获得了足够的细胞病理学分析组织。恶性肿瘤检测的总体敏感性为 0.92(95%置信区间 0.86-0.96);然而,这取决于 EBUS-TBNA 的主要适应证。所有亚组的诊断敏感性均较高,但阴性预测值取决于该操作的临床适应证。我们估计,通过使用 EBUS-TBNA 避免了 104 例侵袭性手术和 32 例住院治疗。完成 20 次操作后,诊断性能显著提高,诊断准确性直到完成 50 次操作后才达到峰值。
EBUS-TBNA 能够准确地从组织学上确认在所有研究的临床适应证中存在的大量疾病过程,包括恶性和良性。即使由经验最少的介入专家进行,该操作也是安全的。在完成 50 例操作后,诊断性能继续提高。